Chemcon increasing pharma intermediate capacities in FY22
Chemical

Chemcon increasing pharma intermediate capacities in FY22

The company is increasing capacities of pharma intermediate chemicals at P8 & P9 thereby further increasing its strength with the existing product portfolio

  • By Pravin Prashant | June 02, 2021

Chemcon Speciality Chemicals Limited, a manufacturer of specialized chemicals, such as HMDS & CMIC which are predominantly used in the pharmaceuticals industry and inorganic bromides, namely Calcium Bromide, Zinc Bromide and Sodium Bromide, which are predominantly used as completion fluids in the oilfields industry, is increasing capacities of pharma intermediate chemicals at P8 and P9 thereby further increasing its strength with the existing product portfolio. 

"Due to the 2nd wave of pandemic, the project commercialization has been delayed by a month. We expect both this unit to commence their production by Q2 FY22 and Q3 FY22 respectively," said Kamal Aggarwal, Chairman & MD, Chemcon Speciality Chemicals Limited. 

"We believe that over the years, we have built strong relationships with our customers, who recognise our technical capabilities and trust our potential to deliver consistently. Post our expansion, we will be well equipped to capture new business opportunities,” added Aggarwal.

 Chemcon Speciality Chemicals Limited is one of the largest manufacturers of CMIC in India and the second largest manufacturer of CMIC worldwide. Further, the company is the only manufacturer of Zinc Bromide and the largest manufacturer of Calcium Bromide in India. The company has seven manufacturing facilities located at Manjusar near Vadodara in Gujarat.

Register Now to Attend NextGen Chemicals & Petrochemicals Summit 2024, 11-12 July 2024, Mumbai

Other Related stories

Startups

Petrochemical

Energy

Digitization